The maximum tolerated dose (MTD) was determined to be 570 mg/m2 administered once a week and showed significant anti-tumor activity in MET-amplified non-small cell lung carcinoma patients (Angevin et al., 2017; Choueiri et al., 2017). This evidence concerns the gene MET and neoplasm.